Actively Recruiting

Age: 18Years - 18Years
All Genders
NCT07170345

Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion

Led by Chinese Academy of Sciences · Updated on 2025-09-12

400

Participants Needed

19

Research Sites

104 weeks

Total Duration

On this page

Sponsors

C

Chinese Academy of Sciences

Lead Sponsor

P

Peking Union Medical College Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Hepatocellular carcinoma (HCC) is a common malignancy in China with a high mortality rate. Its early recurrence and long-term prognosis are closely associated with tumor aggressiveness. Microvascular invasion (MVI), defined as the presence of tumor cells within small branches of the portal or hepatic veins, is a key indicator of malignant biological behavior in HCC. Clinically, MVI is strongly correlated with postoperative early recurrence and serves as an important factor in determining surgical margin extension, adjuvant therapy, and postoperative management strategies. At present, definitive diagnosis of MVI still relies on postoperative pathological examination, and stable, effective preoperative assessment methods are lacking. Although some studies have attempted to predict MVI using preoperative imaging features, their clinical translation remains limited by poor generalizability, weak interpretability, and insufficient cross-center adaptability. This study aims to leverage multiphase preoperative CT imaging, artificial intelligence techniques, and clinical prior knowledge to develop a high-performance, generalizable, and interpretable computer-aided diagnostic system for preoperative prediction of HCC-MVI. An observational, prospective evaluation will be conducted to assess system performance and to facilitate the clinical translation of intelligent diagnostic technologies in real-world practice.

CONDITIONS

Official Title

Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion

Who Can Participate

Age: 18Years - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 69; 18 years
  • Confirmed diagnosis of hepatocellular carcinoma (HCC) based on Chinese Clinical Practice Guidelines for Primary Liver Cancer
  • Eligible for liver surgery (hepatic resection or liver transplantation) as per Chinese Clinical Practice Guidelines for Cancer, including stages Ia, Ib, and IIa
  • Underwent preoperative imaging within 1 month before surgery
  • Histopathological evaluation available with documented microvascular invasion (MVI) status
Not Eligible

You will not qualify if you...

  • History of prior antitumor treatment including surgery, transarterial chemoembolization (TACE), radiofrequency ablation (RFA), systemic therapy, or other preoperative interventions
  • Major vascular invasion, bile duct invasion or thrombosis, extrahepatic metastasis, or lymph node involvement
  • Diffuse hepatocellular carcinoma or tumor rupture with bleeding
  • Missing key data required for primary analysis
  • Poor quality imaging preventing reliable analysis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 19 locations

1

Meng Chao Hepatobiliary Hospital of Fujian Medical University

Fuzhou, Fujian, China

Actively Recruiting

2

Guangdong Provincial Hospital of Traditional Chinese Medicine

Guangzhou, Guangdong, China

Actively Recruiting

3

Zhujiang Hospital

Guangzhou, Guangdong, China

Actively Recruiting

4

Fifth Affiliated Hospital, Sun Yat-Sen University

Zhuhai, Guangdong, China

Actively Recruiting

5

Zhuhai People's Hospital

Zhuhai, Guangdong, China

Actively Recruiting

6

First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China

Actively Recruiting

7

Guizhou Provincial People's Hospital

Guiyang, Guizhou, China

Actively Recruiting

8

Henan Provincial People's Hospital

Zhengzhou, Henan, China

Actively Recruiting

9

Shengjing Hospital

Shenyang, Liaoning, China

Actively Recruiting

10

West China Hospital

Chengdu, Sichuan, China

Actively Recruiting

11

Dazhou Central Hospital

Dazhou, Sichuan, China

Actively Recruiting

12

First Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, China

Actively Recruiting

13

The First People's Hospital of Yunnan Province

Kunming, Yunnan, China

Actively Recruiting

14

Yunnan Cancer Hospital

Kunming, Yunnan, China

Actively Recruiting

15

First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

Actively Recruiting

16

Beijing Tsinghua Changgeng Hospital

Beijing, China

Actively Recruiting

17

Beijing YouAn Hospital

Beijing, China

Actively Recruiting

18

Peking Union Medical College Hospital

Beijing, China

Actively Recruiting

19

Eastern Hepatobiliary Surgery Hospital

Shanghai, China

Actively Recruiting

Loading map...

Research Team

D

Di Dong, Ph.D.

CONTACT

M

Mengjie Fang, Ph.D.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

19

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here